August 21, 2025

Nicox Reports Positive Phase 3 Denali Trial Data

In the phase 3 study, NCX 470 met the primary endpoint of noninferiority to latanoprost in lowering IOP.

Ophthalmology Management

August 17, 2025

FDA Affirms Safety of PFAS-Based Materials in Medical Devices

PFAS used in medical devices are different from the small-molecule PFAS that have been linked to environmental and health concerns.

Contact Lens Spectrum

August 13, 2025

A New Chapter in MIGS Innovation

Glaucoma and advanced anterior segment surgery specialist Dr. Thomas Siempis outlines his clinical experience using iStent infinite® trabecular micro-bypass technology

The Ophthalmologist

August 11, 2025

Diet & Sleep Links to Glaucoma

Diet, sleep, and biochemical mediators: novel insights into glaucoma pathogenesis

The Ophthalmologist

August 08, 2025

Also in the News…

The Ophthalmologist brings you the top news stories and studies of the week

The Ophthalmologist

August 01, 2025

Also in the News…

From million dollar grants for ocular gene therapy treatments to undetected eye disease in the African American population, these are the news stories and studies that caught our attention this week…

The Ophthalmologist

March 06, 2025

The Ophthalmologist Heidelberg Engineering Glaucoma Quiz

How would you determine disease progression in the two glaucoma suspects?

The Ophthalmologist

May 02, 2024

The CorNeat EverPatch: Superior Alternative to Tissue Grafts

First non-degradable bio-integrating device targeting glaucoma tube exposure complications that is tailored for surgeons

The Ophthalmologist

July 14, 2025

Higher-Volume Injections Don’t Elevate Glaucoma Risk

An analysis of real-world data finds no significant pressure increases or glaucoma risk with higher-volume agents aflibercept 8 mg, pegcetacoplan, or avacincaptad pegol.

Retinal Physician